Glad to see the FDA continuing to put the screws to Merck:
Another good headline:
“Merck R&D Hammered by Another Setback as FDA Rejects Anesthesia Drug (Again)”
The story here (again):
Add Associated Press to the mix, with this headline:
“FDA Won’t Approve Merck’s Drug to Reverse Anesthesia Effects”
And into day 2 with this Sugammadex story:
“Regulatory Setback for Merck,” says Zacks:
finance.yahoo.com/news/regulator … 07447.html
Good to see the media and research guys doing their jobs
Yet another Sugammadex headline, this one from The Motley Fool:
“Can Merck Recover From This FDA Rejection?”
Analysts Max Macaluso and David Williamson weigh in:
“This isn’t the only drug that the big pharma company has failed to get past the FDA this year; its insomnia drug suvorexant was also rejected earlier in 2013. What does this most recent rejection mean for investors, and is Merck making the right changes to its research and development structure?.”
Watch the video here:
Merck has accumulated a very scary track record.
Even the drugs which DO get approved are killing people and ruining lives.
Fosamax, Propecia …
My prediction is a combination of FDA pressure and Wall Street disdain for Merck will cause a lot of damage. Not to mention the multi-millions they’ll have to shell out for the Propecia lawsuits.
Time to set up a ‘short sell’ position on their stock imo.
Good points. And, actually, Merck had long been one of the most shorted stocks.
It was recently bounced from its No. 11 position by Exxon Mobil: